Home > Publications database > A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer. > print

001     179273
005     20240229145538.0
024 7 _ |a 10.3390/ph15030267
|2 doi
024 7 _ |a pmid:35337061
|2 pmid
024 7 _ |a pmc:PMC8954540
|2 pmc
024 7 _ |a altmetric:125435208
|2 altmetric
037 _ _ |a DKFZ-2022-00555
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Eder, Ann-Christin
|0 P:(DE-He78)584449af653618bdd9539e668604ad74
|b 0
|e First author
245 _ _ |a A New Class of PSMA-617-Based Hybrid Molecules for Preoperative Imaging and Intraoperative Fluorescence Navigation of Prostate Cancer.
260 _ _ |a Basel
|c 2022
|b MDPI
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1678783786_8936
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a The development of PSMA-targeting low-molecular-weight hybrid molecules aims at advancing preoperative imaging and accurate intraoperative fluorescence guidance for improved diagnosis and therapy of prostate cancer. In hybrid probe design, the major challenge is the introduction of a bulky dye to peptidomimetic core structures without affecting tumor-targeting properties and pharmacokinetic profiles. This study developed a novel class of PSMA-targeting hybrid molecules based on the clinically established theranostic agent PSMA-617. The fluorescent dye-bearing candidates of the strategically designed molecule library were evaluated in in vitro assays based on their PSMA-binding affinity and internalization properties to identify the most favorable hybrid molecule composition for the installation of a bulky dye. The library's best candidate was realized with IRDye800CW providing the lead compound. Glu-urea-Lys-2-Nal-Chx-Lys(IRDye800CW)-DOTA (PSMA-927) was investigated in an in vivo proof-of-concept study, with compelling performance in organ distribution studies, PET/MRI and optical imaging, and with a strong PSMA-specific tumor uptake comparable to that of PSMA-617. This study provides valuable insights about the design of PSMA-targeting low-molecular-weight hybrid molecules, which enable further advances in the field of peptidomimetic hybrid molecule development.
536 _ _ |a 315 - Bildgebung und Radioonkologie (POF4-315)
|0 G:(DE-HGF)POF4-315
|c POF4-315
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
650 _ 7 |a PSMA
|2 Other
650 _ 7 |a guided surgery
|2 Other
650 _ 7 |a hybrid molecules
|2 Other
650 _ 7 |a prostate cancer
|2 Other
650 _ 7 |a theranostics
|2 Other
700 1 _ |a Matthias, Jessica
|b 1
700 1 _ |a Schäfer, Martin
|0 P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa
|b 2
700 1 _ |a Geberlein, Jana
|0 P:(DE-He78)748cbc9500371079bf3d34fc41eb828c
|b 3
700 1 _ |a Steinacker, Nils
|0 P:(DE-He78)b87fdbb732415b24f8c00a8e84109a35
|b 4
700 1 _ |a Bauder-Wüst, Ulrike
|0 P:(DE-He78)033d979f00729281e709b85fe6cae972
|b 5
700 1 _ |a Domogalla, Lisa-Charlotte
|0 P:(DE-He78)e979eb6b4ff6c757f9ff11cc320d5faa
|b 6
700 1 _ |a Roscher, Mareike
|0 P:(DE-He78)1a25bc9516a97a13551ebd083356d24f
|b 7
700 1 _ |a Haberkorn, Uwe
|0 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
|b 8
700 1 _ |a Eder, Matthias
|0 P:(DE-He78)331382460d902d1341dc73db8b990f97
|b 9
700 1 _ |a Kopka, Klaus
|0 P:(DE-He78)9793347ba83f527b81a22ab75af9378a
|b 10
|e Last author
773 _ _ |a 10.3390/ph15030267
|g Vol. 15, no. 3, p. 267 -
|0 PERI:(DE-600)2193542-7
|n 3
|p 267
|t Pharmaceuticals
|v 15
|y 2022
|x 1424-8247
909 C O |p VDB
|o oai:inrepo02.dkfz.de:179273
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 0
|6 P:(DE-He78)584449af653618bdd9539e668604ad74
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 2
|6 P:(DE-He78)3373acf5d3b93adfd9ea973cf2d218aa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 3
|6 P:(DE-He78)748cbc9500371079bf3d34fc41eb828c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 4
|6 P:(DE-He78)b87fdbb732415b24f8c00a8e84109a35
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 5
|6 P:(DE-He78)033d979f00729281e709b85fe6cae972
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 6
|6 P:(DE-He78)e979eb6b4ff6c757f9ff11cc320d5faa
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 7
|6 P:(DE-He78)1a25bc9516a97a13551ebd083356d24f
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 8
|6 P:(DE-He78)13a0afba029f5f64dc18b25ef7499558
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 9
|6 P:(DE-He78)331382460d902d1341dc73db8b990f97
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 10
|6 P:(DE-He78)9793347ba83f527b81a22ab75af9378a
913 1 _ |a DE-HGF
|b Gesundheit
|l Krebsforschung
|1 G:(DE-HGF)POF4-310
|0 G:(DE-HGF)POF4-315
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Bildgebung und Radioonkologie
|x 0
914 1 _ |y 2022
915 _ _ |a Creative Commons Attribution CC BY (No Version)
|0 LIC:(DE-HGF)CCBYNV
|2 V:(DE-HGF)
|b DOAJ
|d 2021-06-15
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-06-15
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-06-15
915 _ _ |a Article Processing Charges
|0 StatID:(DE-HGF)0561
|2 StatID
|d 2021-06-15
915 _ _ |a Fees
|0 StatID:(DE-HGF)0700
|2 StatID
|d 2021-06-15
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b PHARMACEUTICALS-BASE : 2021
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0501
|2 StatID
|b DOAJ Seal
|d 2022-01-15T12:16:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0500
|2 StatID
|b DOAJ
|d 2022-01-15T12:16:46Z
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b DOAJ : Blind peer review
|d 2022-01-15T12:16:46Z
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2022-11-29
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-29
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
|d 2022-11-29
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b PHARMACEUTICALS-BASE : 2021
|d 2022-11-29
920 2 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 0
920 1 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 0
920 1 _ |0 I:(DE-He78)FR01-20160331
|k FR01
|l DKTK FR zentral
|x 1
920 1 _ |0 I:(DE-He78)E060-20160331
|k E060
|l E060 KKE Nuklearmedizin
|x 2
920 1 _ |0 I:(DE-He78)DD01-20160331
|k DD01
|l DKTK DD zentral
|x 3
920 0 _ |0 I:(DE-He78)E030-20160331
|k E030
|l Radiopharmazeutische Chemie
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)E030-20160331
980 _ _ |a I:(DE-He78)FR01-20160331
980 _ _ |a I:(DE-He78)E060-20160331
980 _ _ |a I:(DE-He78)DD01-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21